R-CHOP in DLBCL: priming for success Comment

被引：3
|
作者：
Hertzberg, Mark [1 ]
机构：
[1] Prince Wales Hosp, Hong Kong, Peoples R China
来源：
BLOOD | 2022年 / 139卷 / 08期
关键词：
PHASE-III;
D O I：
10.1182/blood.2021013620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Martin et al(1) report the results of a phase 1 study evaluating a novel strategy of epigenetic priming before rituximab plus cyclo-phosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) using the hypomethylating agent CC486, an oral azacitidine, as initial treatment in patients with high-risk diffuse large B-cell lymphoma (DLBCL) or grade 3B/transformed follicular lymphoma. The authors demonstrate that the addition of CC-486 to R-CHOP shows promising clinical antitumor activity with an acceptable safety profile.
引用
收藏
页码：1121 / 1122
页数：2
相关论文
共 50 条
  • [1] Prognostic PET after R-CHOP in DLBCL
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (04) : 17N - 17N
  • [2] Is it time to stop treating subsets of DLBCL with R-CHOP?
    Moskowitz, C
    [J]. BLOOD, 2006, 107 (11) : 4197 - 4198
  • [3] RESULTS OF R-CHOP AND R-CHOP
    Krasny, Academician Sergei A.
    Konoplya, Natalya E.
    Kalenik, Volha A.
    Dziameshka, Pavel D.
    [J]. DOKLADY NATSIONALNOI AKADEMII NAUK BELARUSI, 2023, 67 (02): : 126 - 133
  • [4] Retrospective Study of Standard R-CHOP Therapy in Localized DLBCL
    Tomita, Naoto
    Takasaki, Hirotaka
    Miyashita, Kazuho
    Fujisawa, Shin
    Ogusa, Eriko
    Matsuura, Shro
    Kishimoto, Kumiko
    Numata, Ayumi
    Fujita, Atsuko
    Ohshima, Rika
    Kuwabara, Hideyuki
    Hagihara, Maki
    Hashimoto, Chizuko
    Takemura, Sachiya
    Koharazawa, Hideyuki
    Yamazaki, Etsuko
    Fujimaki, Katsumichi
    Taguchi, Jun
    Sakai, Rika
    Ishigatsubo, Yoshiaki
    [J]. BLOOD, 2012, 120 (21)
  • [5] Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
    Wilson, Wyndham H.
    Wright, George W.
    Huang, Da Wei
    Hodkinson, Brendan
    Balasubramanian, Sriram
    Fan, Yue
    Vermeulen, Jessica
    Shreeve, Martin
    Staudt, Louis M.
    [J]. CANCER CELL, 2021, 39 (12) : 1643 - +
  • [6] THE INITIAL RESULTS EARLY R-CHOP THERAPY ASSESSMENT USING FLT PET/CT IN PATIENTS WITH DLBCL TREATED WITH R-CHOP
    Malkowski, B.
    Chmielowska, E.
    Olejniczak, M.
    Pietrzak, T.
    Makarewicz, A.
    Szefer, J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 215 - 215
  • [7] Early R-CHOP therapy assessment using FLT PET/CT in patients with DLBCL treated with R-CHOP - the initial results
    Malkowski, B.
    Chmielowska, E.
    Olejnik, M.
    Pietrzak, T.
    Makarewicz, A.
    Kachniarz, A.
    Kasprzak, K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S250 - S251
  • [8] IPI and R-IPI in Korean DLBCL patients treated with R-CHOP
    Bae, Sung-Hwa
    Ryoo, Hun-Mo
    Kim, Min Kyoung
    Lee, Kyung Hee
    Hyun, Myung Soo
    Kim, Hawk
    Park, Jea-Hoo
    Lee, Won-Sik
    Joo, Young-Don
    [J]. BLOOD, 2007, 110 (11) : 191B - 191B
  • [9] Second report of clinical significance of sFas for DLBCL treated with CHOP and new analysis of sFas for DLBCL treated with R-CHOP
    Tsurumi, Hisashi
    Hara, Takeshi
    Kitagawa, Jun-ichi
    Goto, Naoe
    Kanemura, Nobuhiro
    Kasahara, Senji
    Yamada, Toshiki
    Moriwaki, Hisataka
    [J]. BLOOD, 2007, 110 (11) : 469A - 469A
  • [10] Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL
    Marshall, Shoko
    Nishimura, Noriko
    Inoue, Norihito
    Yamauchi, Hirofumi
    Tsuyama, Naoko
    Takeuchi, Kengo
    Mishima, Yuko
    Yokoyama, Masahiro
    Ogasawara, Toshie
    Mori, Naoki
    Ogawa, Tetsuya
    Sakura, Hiroshi
    Terui, Yasuhito
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 162 - 169
12345